Who is sponsoring NCT06204939?

NCT06204939 is sponsored by L. van Hogezand.

What drugs are being tested in NCT06204939?

Interventions in NCT06204939: Randomizing for EPGB procedure, Randomizing for OAGB procedure.

What condition does NCT06204939 study?

NCT06204939 studies Bariatric Surgery Candidate.

Is NCT06204939 still recruiting?

NCT06204939 is currently not yet recruiting. Last updated 12 January 2024.

Last reviewed 2024-01-12 · How we verify

NCT06204939: EXPANT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extended Pouch Gastric Bypass vs One-anastomosis Gastric Bypass in Patients With BMI≥45

Not yet recruiting NA Last updated 12 January 2024

What this trial tests

NA trial testing Randomizing for EPGB procedure in Bariatric Surgery Candidate in 250 participants. Not yet recruiting.

Timeline

1 June 2024

Primary endpoint
1 December 2025

1 December 2029

Quick facts

Lead sponsor	L. van Hogezand
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	250
Start date	1 June 2024
Primary completion	1 December 2025
Estimated completion	1 December 2029

Drugs / interventions tested

Randomizing for EPGB procedure
Randomizing for OAGB procedure

Conditions studied

Bariatric Surgery Candidate — all drugs for Bariatric Surgery Candidate →

Sponsor

L. van Hogezand

Who can join

Adults 18 to 65, any sex, with Bariatric Surgery Candidate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The classic RYGB is in most patients with a BMI ≥45 technically not feasible. Two alternatives are the Extended Pouch Gastric Bypass and the One Anastomosis gastric bypass. In this single blinded randomized controlled trial the investigators aim to establish which technique leads to more weightloss in bariatric patients with a BMI ≥45.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bariatric Surgery Candidate

Currently open trials in the same condition.

NCT07525232 — Stepwise PEEP vs Sustained Inflation in Bariatric Surgery Patients · NA · recruiting
NCT06511310 — Exercise, Brain Activity, and Weight Maintenance · NA · recruiting
NCT05966727 — Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients · NA · recruiting
NCT06915558 — Modulation of the Inflammatory Response in Bariatric Surgery · recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06204939 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by L. van Hogezand
Last refreshed: 12 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06204939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing